• Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National Drug Formulary. However, currently, it is also used for indications not specified in the National Drug Formulary.
  • Adding cetuximab to chemotherapy for mCRC is unlikely to offer “good value for money” in Indonesia. Furthermore, there are meager benefit, in terms of life years gained.
  • With regards to affordability, government requires a lot of money to provide cetuximab as an adjuvant therapy for mCRC patients. There should be a careful consideration whether cetuximab remains on benefit package in national health insurance scheme.